Scientific Sessions 2025  /  Biological and Pragmatic Interventions in Heart Failure: From Present to Future  /  Discussant: DAPA-EAT
Logo

American Heart Association

  78
  0

Final ID:

Discussant: DAPA-EAT

  • Fontana, Marianna  ( University College London , London , United Kingdom )
  • Raman, Subha  ( OhioHealth , Columbus , Ohio , United States )
    • Author Disclosures:
    Marianna Fontana: DO have relevant financial relationships ; Consultant:Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium:Active (exists now) ; Individual Stocks/Stock Options:Mycardium (shares):Active (exists now) ; Individual Stocks/Stock Options:LexeoTherapeutics (share options):Active (exists now) ; Other (please indicate in the box next to the company name):Alnylam, Bridgbio, Astrazeneca, Pfizer.(research grants):Active (exists now) | Subha Raman: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Biological and Pragmatic Interventions in Heart Failure: From Present to Future

Sunday, 11/09/2025 , 08:00AM - 09:15AM

Featured Science

More abstracts on this topic:
ANSWER-HF: A Randomized Controlled Trial of Sacubitril/Valsartan Versus Enalapril in Patients with Chronic Chagas Cardiomyopathy and Reduced Ejection Fraction

Madrini Junior Vagner, Antunes Talita, Damiani Lucas, Jose Grupi Cesar, Mathias Junior Wilson, Lopes Renato, Ramires Felix, Ramos Souza Paulo, Fernandes Fabio, Maria Ianni Barbara, Silva Martins Alan, JadÁn Luzuriaga Georgina Del Cisne, Cardoso Barbosa Fonseca Keila, Ribeiro Orlando, Bispo Da Cruz Allecineia

Discussant: The MAPLE-HCM Trial

Day Sharlene

More abstracts from these authors:
Stiffen Up: Evaluation of HFpEF in the Patient with Cancer

Fontana Marianna, Sarswat Nitasha, Ruberg Frederick

Meet the Trialist: Nexiguran ziclumeran (nex-z, also known as NTLA-2001), an investigational in vivo CRISPR-based therapy for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM): interim report of the Phase 1 study

Fontana Marianna

You have to be authorized to contact abstract author. Please, Login
Not Available